Cat. No. 4176
Chemical Name: (2R,6S-rel)-2,6-Dimethyl-N-[5-[6-(4
Biological ActivityPotent ATM kinase inhibitor (IC50 = 6.3 nM). Exhibits little to no nonspecific target effects against a panel of 229 protein kinases; displays similar target selectivity to KU 55933 (Cat. No. 3544). Inhibits migration and invasion of human glioma cells in vitro.
Licensing InformationSold with the permission of AstraZeneca.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Golding et al (2009) Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol.Cancer Ther. 8 2894. PMID: 19808981.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for KU 60019 include:
Mehta et al (2015) Human papillomaviruses activate and recruit SMC1 cohesin proteins for the differentiation-dependent life cycle through association with CTCF insulators. PLoS Pathog 11 e1004763. PMID: 25875106.
Barton et al (2014) Polo-like kinase 3 regulates CtIP during DNA double-strand break repair in G1. J Cell Biol 206 877. PMID: 25267294.
Davari et al (2014) Checkpoint kinase 2 is required for efficient immunoglobulin diversification. Cell Cycle 13 3659. PMID: 25483076.
Rass et al (2013) Ataxia telangiectasia mutated (ATM) is dispensable for endonuclease I-SceI-induced homologous recombination in mouse embryonic stem cells. J Biol Chem 288 7086. PMID: 23355489.
View Related Products by Product Action
Keywords: KU 60019, supplier, Astrazeneca, KU60019, atm, kinases, ataxia, telangiectasia, mutated, potent, inhibitors, inhibits, Tocris Bioscience, ATM and ATR Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent PKCβ inhibitorBMS 265246
Potent cdk1/2 inhibitorAutocamtide-2-related inhibitory peptide, myristoylated
CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptideMP A08
Selective ATP competitive SphK1 and 2 inhibitor; cell permeableAkti-1/2
Potent and selective dual Akt1 and 2 inhibitorVX 680
High affinity and selective Aurora kinase inhibitorImatinib mesylate
Potent and selective v-Abl tyrosine kinase inhibitor; also inhibits PDGFR and c-kitTGX 221
Potent and selective PI 3-kinase β inhibitorPF 543 hydrochloride
Potent and selective SphK1 inhibitorJX 06
Potent and selective PDK1/2/3 inhibitorMRT 68601 hydrochloride
Potent TBK1 inhibitorAzoramide
Unfolded protein response (UPR) modulatorLCB 03-0110 dihydrochloride
Potent c-SRC kinase inhibitor; also inhibits DDR2, BTK and SykCCT 241533 dihydrochloride
Potent Chk2 inhibitorIRAK1/4 Inhibitor I
IRAK4 and IRAK1 inhibitorCentrinone
High affinity and selective PLK4 inhibitorAZD 3147
Potent and selective dual mTORC1 and 2 inhibitor; orally bioavailable
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.